Company intelligence / Profile preview

Camstent

Bedford/Sharnbrook, England, United Kingdomcamstent.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Camstent’s anti-microbial polymer-coated Foley catheter has shown 61%-98% reduction in biofilm formation in a cohort of 95 patients. The device is currently undergoing further clinical studies within NHS hospitals in the UK. Earlier pilot and proof-of-concept data are positive, but no large-scale commercial launch or pivotal trial results have been reported yet.

Therapeutic areas: Infectious Diseases
Modalities: DevicePolymer-drug conjugate therapy
Industry: Therapeutic Medical Devices

Partnerships

National Health Service (NHS) hospitals within the UK for clinical evaluation and supply

Beyond the preview

Go deeper on Camstent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Camstent.

Explore the full profile